ES2191070T3 - Arilalquil-piridazinonas. - Google Patents

Arilalquil-piridazinonas.

Info

Publication number
ES2191070T3
ES2191070T3 ES96105702T ES96105702T ES2191070T3 ES 2191070 T3 ES2191070 T3 ES 2191070T3 ES 96105702 T ES96105702 T ES 96105702T ES 96105702 T ES96105702 T ES 96105702T ES 2191070 T3 ES2191070 T3 ES 2191070T3
Authority
ES
Spain
Prior art keywords
sup
piridazinonas
arilalquil
phosphodiestarasa
allergies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96105702T
Other languages
English (en)
Inventor
Rochus Dr Jonas
Michael Dr Wolf
Norbert Dr Beier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Application granted granted Critical
Publication of ES2191070T3 publication Critical patent/ES2191070T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

ARILALQUIL-PIRIDAZINONAS DE FORMULA I Y SUS SALES FISIOLOGICAMENTE ACEPTABLES EN DONDE R{SUP,1}, R{SUP,2}, R{SUP,3}, R{SUP,4}, R{SUP,5} Y Q TIENEN LOS SIGNIFICADOS DADOS EN LA REIVINDICACION 1, POSEEN UN EFECTO INHIBIDOR DE LA FOSFODIESTARASA IV Y SE PUEDEN UTILIZAR EN EL TRATAMIENTO DE PROCEDIMIENTO INFLAMATORIOS ASI COMO EN ALERGIAS, ASMA Y ENFERMEDADES AUTOINMUNES.
ES96105702T 1995-04-20 1996-04-11 Arilalquil-piridazinonas. Expired - Lifetime ES2191070T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19514568A DE19514568A1 (de) 1995-04-20 1995-04-20 Arylalkyl-pyridazinone

Publications (1)

Publication Number Publication Date
ES2191070T3 true ES2191070T3 (es) 2003-09-01

Family

ID=7759974

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96105702T Expired - Lifetime ES2191070T3 (es) 1995-04-20 1996-04-11 Arilalquil-piridazinonas.

Country Status (21)

Country Link
US (2) US6399611B1 (es)
EP (1) EP0738715B1 (es)
JP (1) JP4005157B2 (es)
KR (1) KR100428879B1 (es)
CN (1) CN1159299C (es)
AT (1) ATE231842T1 (es)
AU (1) AU705025B2 (es)
CA (1) CA2174472C (es)
CZ (1) CZ291868B6 (es)
DE (2) DE19514568A1 (es)
DK (1) DK0738715T3 (es)
ES (1) ES2191070T3 (es)
HU (1) HU226198B1 (es)
NO (1) NO307931B1 (es)
PT (1) PT738715E (es)
RU (1) RU2159236C2 (es)
SI (1) SI0738715T1 (es)
SK (1) SK284167B6 (es)
TW (1) TW475927B (es)
UA (1) UA43853C2 (es)
ZA (1) ZA963154B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19533975A1 (de) * 1995-09-14 1997-03-20 Merck Patent Gmbh Arylalkyl-diazinone
JP4017214B2 (ja) 1996-06-11 2007-12-05 興和創薬株式会社 ５−フェニル−３−ピリダジノン誘導体
EP0924204A4 (en) * 1996-08-27 2002-10-23 Nikken Chemicals Co Ltd 2-PHENYLMORPHOLIN-5-ONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
DE19850701A1 (de) * 1998-11-04 2000-05-11 Merck Patent Gmbh Benzoylpyridazine
IL147688A0 (en) 1999-08-21 2002-08-14 Byk Gulden Lomberg Chem Fab Synergistic combination
DE10064997A1 (de) * 2000-12-23 2002-06-27 Merck Patent Gmbh Benzoylpyridazine
JP2004521928A (ja) * 2001-02-12 2004-07-22 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング ４型ホスホジエステラーゼ阻害剤の心筋疾患における使用
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
KR20040007596A (ko) * 2001-05-23 2004-01-24 다나베 세이야꾸 가부시키가이샤 골절 치료 촉진용 조성물
JP4510383B2 (ja) 2001-05-23 2010-07-21 田辺三菱製薬株式会社 軟骨疾患修復治療用組成物
DE10150517A1 (de) * 2001-10-12 2003-04-17 Merck Patent Gmbh Verwendung von Phosphodiesterase IV-Inhibitoren
MXPA04003668A (es) * 2001-10-31 2004-07-22 Merck Patent Gmbh Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
US7074959B2 (en) * 2002-08-01 2006-07-11 New Mexico Highlands University Methods and systems for remediating hydrazine-contaminated equipment and/or surfaces
KR20050115331A (ko) 2003-04-01 2005-12-07 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. 불임증 포스포디에스터라제의 억제제
US20080227790A1 (en) * 2004-02-04 2008-09-18 Altana Pharma Ag Pyridazinone Derivatives and their Use as Pde4 Inhibitors
DE602005005638T2 (de) 2004-02-04 2009-05-14 Nycomed Gmbh 2-(piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-on-derivate als pde4-inhibitoren
TW200848036A (en) * 2006-12-14 2008-12-16 Astellas Pharma Inc Novel oxycarbonyl compound
US8466198B2 (en) * 2008-09-02 2013-06-18 Bruce Kneller Compositions comprising creatine salts and methods of use thereof
US20110052729A1 (en) * 2009-08-26 2011-03-03 Golini Jeffrey M Pharmaceutical or nutraceutical composition
MX2022008085A (es) 2016-03-16 2022-07-11 H Lee Moffitt Cancer Ct & Res Moleculas peque?as contra cereblon para mejorar la funcion efectora de los linfocitos t.
EA202190248A1 (ru) 2018-07-11 2021-06-16 Х. Ли Моффитт Кэнсер Сентер Энд Рисерч Инститьют, Инк. Димерные иммуномодулирующие соединения против механизмов на основе цереблона

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1604863A (es) * 1967-11-22 1972-04-17
US3975388A (en) * 1971-02-22 1976-08-17 Bdh Pharmaceuticals Limited Pyridazinones
DE2845456A1 (de) * 1978-10-19 1980-08-14 Merck Patent Gmbh 6-arylpyridazin-3-one und verfahren zu ihrer herstellung
US4397854A (en) * 1981-05-14 1983-08-09 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
US4734415A (en) * 1982-08-13 1988-03-29 Warner-Lambert Company Substituted 4,5-dihydro-6-(substituted)-phenyl-3(2H)-pyridazinones and 6-(substituted) phenyl-3(2H)-pyridazinones
NZ208107A (en) * 1983-05-11 1986-12-05 Byk Gulden Lomberg Chem Fab 6-aryl-3(2h)-pyridazinones and pharmaceutical compositions
US4666902A (en) 1983-06-20 1987-05-19 Cassella Aktiengesellschaft Tetrahydropyridazinone derivatives, processes for their preparation and their use
US4816454A (en) 1984-09-21 1989-03-28 Cassella Aktiengesellschaft 4,5-dihydro-3(2H)-pyridazinones and their pharmacological use
JPS61158969A (ja) * 1984-12-24 1986-07-18 ワーナー‐ランバート・コンパニー ４，５‐ジヒドロ‐４，４‐ジアルキル‐６‐（置換）フエニル‐３（２ｈ）‐ピリダジノン類
DE3704879A1 (de) * 1987-02-17 1988-08-25 Merck Patent Gmbh Pyridazinonderivate
GB8903130D0 (en) 1989-02-11 1989-03-30 Orion Yhtymae Oy Substituted pyridazinones
AU6081690A (en) * 1989-08-10 1991-02-14 Glaxo Inc. Pyridazinones having cardiotonic and beta block activity
DE4237656A1 (de) * 1992-06-13 1993-12-16 Merck Patent Gmbh Benzimidazolderivate
JP2806192B2 (ja) * 1992-11-02 1998-09-30 日本曹達株式会社 血小板凝集抑制剤
DE19502699A1 (de) * 1995-01-28 1996-08-01 Merck Patent Gmbh Arylalkyl-thiadiazinone

Also Published As

Publication number Publication date
SI0738715T1 (en) 2003-10-31
US6399611B1 (en) 2002-06-04
TW475927B (en) 2002-02-11
DK0738715T3 (da) 2003-05-26
KR960037662A (ko) 1996-11-19
NO961578D0 (no) 1996-04-19
UA43853C2 (uk) 2002-01-15
CZ291868B6 (cs) 2003-06-18
CN1159299C (zh) 2004-07-28
NO961578L (no) 1996-10-21
DE59610081D1 (de) 2003-03-06
CN1142493A (zh) 1997-02-12
JP4005157B2 (ja) 2007-11-07
US6531473B2 (en) 2003-03-11
DE19514568A1 (de) 1996-10-24
CA2174472A1 (en) 1996-10-21
EP0738715A3 (de) 1998-06-17
EP0738715A2 (de) 1996-10-23
AU5071196A (en) 1996-10-31
PT738715E (pt) 2003-06-30
ZA963154B (en) 1996-12-06
SK284167B6 (sk) 2004-10-05
AU705025B2 (en) 1999-05-13
ATE231842T1 (de) 2003-02-15
HUP9601034A3 (en) 1999-03-01
HU9601034D0 (en) 1996-06-28
HUP9601034A2 (en) 1996-12-30
JPH08291145A (ja) 1996-11-05
RU2159236C2 (ru) 2000-11-20
CZ113296A3 (en) 1996-11-13
EP0738715B1 (de) 2003-01-29
SK48796A3 (en) 1997-02-05
KR100428879B1 (ko) 2004-07-15
HU226198B1 (en) 2008-06-30
NO307931B1 (no) 2000-06-19
US20020111356A1 (en) 2002-08-15
CA2174472C (en) 2008-10-21

Similar Documents

Publication Publication Date Title
ES2191070T3 (es) Arilalquil-piridazinonas.
ES2192213T3 (es) Arilalquil-diazinonas como inhibidores de fosfodiesterasa iv.
ES2191192T3 (es) Tienopirimidinas.
ES2189235T3 (es) 6-fenilfenantridinas sustituidas.
ES2162942T3 (es) Nuevos derivados de acidos carboxilicos, su obtencion y empleo.
ES2174465T3 (es) Compuestos triazol y su utilizacion como ligandos de dopamina-d.
HUP0004592A2 (hu) VCAM-1 expresszió gátlására alkalmas vegyületek és eljárások
AR010062A1 (es) Nuevos benzamidaldehidos y su utilizacion
YU21401A (sh) Tetrahidropiridoetri
ES2186015T3 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol.
ES2192839T3 (es) Timosina beta 4 oxidada.
PT882021E (pt) Novas fenantridinas
TR200200160T2 (tr) Antiinflamatuar ajanlar olarak imidazoller ve triazoller
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
FI953748A (fi) Yhdisteitä, joilla on sekä voimakas kalsium antagonisti- että antioksidanttiaktiivisuus sekä niiden käyttö solua suojaavina aineina
ES2115985T3 (es) Dihidropirazolopirroles.
MA28010A1 (fr) Derives de piperazine et leur utilisation comme agents therapeutiques
DE60045508D1 (de) Dalda-analoge und ihre verwendung
DE69839696D1 (de) Anellierte dihydropyrane
SE9802208D0 (sv) Novel compounds
ES2163735T3 (es) Compuestos biarilos heterociclicos, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
ATE386742T1 (de) Imidazonaphthyridine
DE60115466D1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
DE69823493D1 (de) Tetrahydropyridoverbindungen
AR035284A1 (es) Formulaciones en combinacion de derivados de propanol-amina sustituidos con arilo, junto con otras sustancias activas y su utilizacion